Clinical Trials for Prinicipal Investigator: Daniela Bota

13 Open Trials. Phone:(877.827.8839)
Protocol No. Title Status
ALLIANCE-A071601 Phase II Trial of BRAF/MEK Inhibitors in Papillary Craniopharyngiomas Open
ALLIANCE-A221101 ALLIANCE-A221101-A Phase III Randomized, Double-Blind Placebo Controlled Study of Armodafinil (Nuvigil®) To Reduce Cancer-Related Fatigue in Patients with High Grade Glioma Open
ECOG-EAY131 Molecular Analysis for Therapy Choice (MATCH) Open
SWOG-S1609 DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors Open
UCI-12-18 (BIOREPOSITORY PROTOCOL) Comprehensive, Coordinated Clinical, Imaging and Histological Database for the Study of Neurological Outcomes of Cancer and Cancer Treatments Open
UCI-14-58 Phase I, Multi-Center, Open-Label, Dose-Escalation, Combination Study of Marizomib and Bevacizumab in Bevacizumab-Naïve Subjects with WHO Grade IV Malignant Glioma Followed by Phase II Studies of Single Agent Marizomib and Combination Marizomib and Bevacizumab, and Phase I Dose-Escalation Study of Enternally-Administered Marizomib with Bevacizumab Open
UCI-15-79 Phase II Open-Label Randomized Study of Radiosurgery with or without Tumor Treating Fields (TT Fields) for 1-10 Brain Metastases from Non-Small Cell Lung Cancer (NSCLC) Open
UCI-16-22 A Phase III, Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Eflornithine with Lomustine Compared to Lomustine Alone in Patients with Anaplastic Astrocytoma that Progress/Recur After Irradiation and Adjuvant Temozolomide Chemotherapy Open
UCI-16-54 Identification of Functional MRI, Neuropsychiatric, and Circulating VEGF Changes After Marizomib Treatment in Patients Enrolled in the UCI 14-58 Study (Single Agent Marizomib Cohort) Open
UCI-16-74 A Phase III Open-Label, Randomized, Multicenter Study of NKTR-102 versus Treatment of Physician's Choice (TPC) in Patients with Metastatic Breast Cancer who Have Stable Brain Metastases and Have Been Previously Treated with an Anthracycline, a Taxane, and Capecitabine Open
UCI-17-115 Phase II trial of AV-GBM-1 (autologous dendritic cells loaded with autologous tumor associated antigens) as an adjunctive therapy following primary surgery plus concurrent chemoradiation in patients with newly diagnosed glioblastoma Open
UCI-17-88 Open-label, Randomized, Controlled, Phase III Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) with Radiation Therapy and Temozolomide in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects Open
UCI-18-98 Right to Try Use of ERC1671 to Treat Glioblastoma Multiforme (GBM) Open